Non-Listed Company Roadshow


13:30 PM-16:50 PM
    Moderator
  • 何风志, 北康医疗投资管理有限公司总经理
  • HE Fengzhi, General Manager, Beikang Healthcare
13:30 PM-13:55 PM
  • 项目1
  • Project 1
  • COVID-19表位肽疫苗CoVac501研发
  • Development of CoVac501, A Multiple Epitope Peptide Vaccine for COVID-19
  • 宫丽崑,中国科学院上海药物研究所课题组长,教授
  • GONG Likun,PI, Professor, Shanghai Institute of Materia Medica
13:55 PM-14:20 PM
  • 项目2
  • Project 2
  • 利用组合技术平台 开发全球新一代的抗肿瘤小分子药物
  • Utilizing Integrated Technology Platforms to Develop Next-Generation Cancer Therapeutics
  • 王奎锋,勤浩医药(苏州)有限公司创始人&CEO
  • WANG Kuifeng, Founder & CEO, Suzhou Genhouse Bio Co., Ltd.
14:20 PM-14:45 PM
  • 项目3
  • Project 3
  • 创新点亮生命——维昇药业TransCon技术平台产品研发进展
  • Innovation Brings light to life——VISEN Pharma Innovative Pipeline Development Leveraging TransCon Technology
  • 卢安邦, 维昇药业CEO
  • Pony LU, CEO, VISEN Pharmaceuticals
14:45 PM-15:10 PM
  • 项目4
  • Project 4
  • 皮卡佐剂在创新性疫苗中的应用
  • Application of PIKA Adjuvant in Innovative Vaccines
  • 邵辉, 依生生物首席执行官
  • SHAO Hui,CEO, YishengBio
15:10 PM-15:35 PM
  • 项目5
  • Project 5
  • 英派药业——小分子,大影响:打造全球领先的合成致死机制产品组合
  • IMPACT Therapeutics——Small Molecule, Big Impact: Building Leading Global Synthetic Lethality Product Pipeline
  • 包骏, 英派药业总裁兼首席执行官
  • BAO Jun,President & CEO, Impact Therapeutics
15:35 PM-16:00 PM
  • 项目6
  • Project 6
  • 基于膜蛋白胞内滞留技术的通用型CAR-T:平台技术开发及临床探索
  • Allogeneic CAR-T Platform Based on Intracellular Retention of Membrane Proteins: Technology Development and Clinical Investigation
  • 李俊, 苏州方德门达新药开发有限公司总经理
  • LI Jun,General Manager, Suzhou Fundamenta Therapeutics Inc.
16:00 PM-16:25 PM
  • 项目7
  • Project 7
  • 无疆科技——专注于脑科学研究和中枢神经疾病干预的数字疗法
  • Beijing Infinite Brain Technologies——Aims to Provide Digital Curative Solutions for Central Nervous System (CNS) Diseases
  • 张类波, 北京无疆脑智科技有限公司首席运营官
  • Angela ZHANG, COO, Beijing Infinite Brain Technologies
16:25 PM-16:50 PM
  • 项目8
  • Project 8
  • 用于治疗复发难治多发性骨髓瘤及其他多种肿瘤的新一代蛋白酶体抑制剂的研发
  • Development of A New Generation of Proteasome Inhibitors for the TreatMent of Relapsed and Refractory Multiple Myeloma and Other Tumors
  • 仲为栋, 宁波圣健生物医药科技有限公司商务总监
  • ZHONG Weidong,Business Development Director, Ningbo Shengjian Biopharmaceutical Tech. Co., Ltd.
Specification:
  • Released: September 17, 2020
  • Last update: September 19, 2020
  • Version: 1.1